Tuesday, 02 January 2024 12:17 GMT

Crescent Biopharma To Present At November Investor Conferences


(MENAFN- GlobeNewsWire - Nasdaq) WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the“Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

  • Guggenheim 2 nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.
  • Stifel 2025 Healthcare Conference, fireside chat on Wednesday, November 12, 2025, at 1:20 p.m. ET in New York.
  • Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 19, 2025, at 9:30 a.m. GMT (4:30 a.m. ET) in London.

A live webcast of each presentation will be available in the Investors section of Crescent's website at , and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company's pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit and follow the Company on LinkedIn and X.

Contact:

Amy Reilly
Chief Communications Officer
...
617-465-0586


MENAFN05112025004107003653ID1110298750



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search